Corbus Pharmaceu Stock Price, News & Analysis

Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) reported a net loss of $8.8 million for Q3 2022 compared to $2.2 million in Q3 2021, influenced by a prior year tax credit. Operating expenses decreased to $8.2 million from $14.0 million due to reduced clinical trial costs. The company is advancing its CRB-601 therapy, with IND submission planned for mid-2023, and positive pre-clinical data will be presented at SITC 2022. Cash reserves of $67 million are expected to support operations through Q2 2024.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) announced a poster presentation at the SITC 2022 Annual Meeting scheduled for November 8-12, 2022. The presentation will highlight the preclinical validation of CRB-601, a selective integrin αvβ8 blocking antibody that shows potent anti-tumor activity in anti-PD-1 resistant models. Investigational New Drug (IND) enabling studies are in progress, with plans to explore its clinical anti-tumor activity in 2023. The poster will be available on the Company's website on November 10.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) announced the appointment of Anne Altmeyer, PhD, MBA, MPH to its board of directors. With extensive experience in oncology R&D and corporate development, Altmeyer aims to enhance Corbus' pipeline and business strategies. Currently serving as President and CEO of TigaTx, she has held leadership roles at Sigilon Therapeutics and Novartis, among others. This appointment is expected to drive growth and innovation in developing immune-oncology therapeutics.

Corbus Pharmaceuticals (NASDAQ: CRBP) presented promising preclinical data for its novel oral cannabinoid, CRB-913, at the European Association for the Study of Diabetes 2022 Annual Conference. CRB-913, a CB1 inverse agonist, demonstrated significant anti-obesity effects by reducing body weight, fat content, and liver triglycerides in diet-induced obesity mouse models. Notably, CRB-913 enhanced the efficacy of incretin analogues such as liraglutide, semaglutide, and tirzepatide, suggesting a potential for combination therapy that could improve current obesity treatments.

Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) announced that CEO Yuval Cohen will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The presentation will be available on-demand starting September 12, 2022, at 7:00 AM ET for registered attendees, accessible for 30 days on the conference platform. Corbus focuses on immunology and is committed to innovative treatments targeting serious illnesses, with a pipeline that includes anti-integrin monoclonal antibodies and small molecules for the endocannabinoid system.

Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) provided an update, highlighting promising pre-clinical data for CRB-601, showing enhanced anti-tumor activity when combined with anti-PD-1 therapy. The IND submission for CRB-601 is on track for mid-2023. The company reported a net loss of $13.2 million for Q2 2022, improved from $17.1 million year-over-year, with operating expenses significantly reduced. Cash reserves stand at $74 million, expected to sustain operations through Q1 2024. Corbus also explores partnerships for advancing its pipeline and non-dilutive funding.

Corbus Pharmaceuticals (NASDAQ: CRBP) presented new preclinical data for its anti-αvβ8 integrin monoclonal antibody, CRB-601, at the NYAS Frontiers in Cancer Immunotherapy Conference. The data highlight CRB-601's significant anti-tumor effects, both as a standalone treatment and in combination with anti-PD-1 therapy, across various tumor models including immune-excluded ones. Notably, CRB-601 enhances T-cell proliferation and re-sensitizes tumors to checkpoint inhibition. The company is advancing towards an IND submission in the first half of 2023.

Corbus Pharmaceuticals (CRBP) reported promising pre-clinical data for CRB-601, showing enhanced anti-tumor activity in combination with anti-PD1 therapy. The IND submission for CRB-601 is on track for the first half of 2023. The company holds $86.8 million in cash, sufficient to fund operations into Q1 2024. They also noted a reduced net loss of $9.4 million for Q1 2022, down from $16 million in Q1 2021, mainly due to lower clinical and manufacturing costs. Corbus aims to expand its immuno-oncology pipeline through strategic partnerships.

Corbus Pharmaceuticals (NASDAQ: CRBP) presented its first preclinical data for CRB-601 at the AACR Annual Meeting on April 8-13, 2022. CRB-601, a monoclonal antibody, targets αvb8 integrin to inhibit TGFb activation in tumors. The data revealed significant tumor growth inhibition in a colon cancer model, enhancing CD8-positive T cell infiltration. The company plans to submit an IND for CRB-601 in H1 2023, aiming to explore its anti-tumor potential in conjunction with existing immune therapies. The full poster and corporate presentation are available on their website.